Fundamental Analysis of GENERATION BIO CO(NASDAQ:GBIO) stock

Fundamental Rating

Taking everything into account, GBIO scores 3 out of 10 in our fundamental rating. GBIO was compared to 588 industry peers in the Biotechnology industry. GBIO has a great financial health rating, but its profitability evaluates not so good. GBIO is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

GBIO had negative earnings in the past year.

In the past year GBIO has reported a negative cash flow from operations.

GBIO had negative earnings in each of the past 5 years.

GBIO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

GBIO has a better Return On Assets (-33.79%) than 67.58% of its industry peers.

GBIO has a better Return On Equity (-62.33%) than 60.41% of its industry peers.

		Industry Rank	Sector Rank
ROA	-33.79%
ROE	-62.33%
ROIC	N/A

ROA(3y)-31.7%

ROA(5y)-53.62%

ROE(3y)-47.3%

ROE(5y)-106.53%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GBIO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.

GBIO has more shares outstanding than it did 1 year ago.

GBIO has more shares outstanding than it did 5 years ago.

GBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -1.87, we must say that GBIO is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of GBIO (-1.87) is comparable to the rest of the industry.

GBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.87

ROIC/WACCN/A

WACC9.27%

2.3 Liquidity

A Current Ratio of 6.83 indicates that GBIO has no problem at all paying its short term obligations.

With a decent Current ratio value of 6.83, GBIO is doing good in the industry, outperforming 67.06% of the companies in the same industry.

A Quick Ratio of 6.83 indicates that GBIO has no problem at all paying its short term obligations.

GBIO has a Quick ratio of 6.83. This is in the better half of the industry: GBIO outperforms 67.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.83
Quick Ratio	6.83

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.60%, which is quite good.

The Revenue has been growing by 171.53% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)16.6%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q3.64%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y171.53%

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, GBIO will show a small growth in Earnings Per Share. The EPS will grow by 3.96% on average per year.

GBIO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.30% yearly.

EPS Next Y22.6%

EPS Next 2Y14.98%

EPS Next 3Y13.58%

EPS Next 5Y3.96%

Revenue Next Year103.8%

Revenue Next 2Y31.61%

Revenue Next 3Y24.3%

Revenue Next 5Y-18.3%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GBIO. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GBIO. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as GBIO's earnings are expected to grow with 13.58% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y14.98%

EPS Next 3Y13.58%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GBIO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENERATION BIO CO

NASDAQ:GBIO (5/3/2024, 8:37:11 AM)

3.28

+0.17 (+5.47%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap218.05M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-33.79%
ROE	-62.33%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.83
Quick Ratio	6.83
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)16.6%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y22.6%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

GENERATION BIO CO (GBIO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens